[1] | Sun. L, Dai. J. J, Hu. W. F and Wang. J, 2016, Expression of Toll-Like Receptors in Hepatic Cirrhosis and Hepatocellular Carcinoma Genet Mol Res 15, (2). |
[2] | Mohamoud Y, Mumtaz G, Riome S, Miller D and Abu-Raddad L, 2013, The epidemiology of hepatitis C virus in Egypt, a systematic review and data synthesis. BMC Infectious Diseases, 13: 288. |
[3] | Naggie S, Patel K and McHutchison J, 2010, Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors. J Antimicrob Chemother; 65M, m2063–2069. |
[4] | Kumar H, Kawai T and Akira S, 2011, Pathogen recognition by the innate immune system. Int. Rev. Immunol. 30: 16-34. |
[5] | Yin S and Gao B, 2010, Toll-Like Receptor 3 in Liver Diseases Gastroenterology Research and Practice Volume 2010, Article ID 750904, 1:6. |
[6] | Zampino. R, Marrone A, Restivo L, et al, 2013, Chronic HCV infection and inflammation: clinical impact on hepatic and extra-hepaticmanifestations,” World J of Hepatol, 5, 10, 528–540. |
[7] | Deluca. S, Ng D, Wortzman. G, Watts T. H., Gommerman J. L., 2011, LTβR signaling in dendritic cells induces a type I IFN response that is required for optimal clonal expansion of CD8+ T cells. Proc. Natl. Acad. Sci. U.S.A. 108, 2046–205110. |
[8] | Al-Anazi M, Nasri .S, Ayman A. Abdo. A, Sanai F et al, 2017, Association of Toll-Like Receptor 3 Single-Nucleotide Polymorphisms and Hepatitis C Virus Infection J Immunol Res. 2017: 1590653Article ID 1590653, 1:6. |
[9] | Esparza M, Manzano M, Alcaraz A, and eñarrubia P, 2015, Inflammatory status in human hepatic cirrhosis World J Gastroenterol, 7, 21(41), 11522–11541. |
[10] | Mukherjee S, Sorrell MF 2008, Controversies in liver transplantation for hepatitis C. Gastroenterology, 134, 1777–88. |
[11] | Innes HA, Hutchinson SJ, Barclay S, Cadzow E, et al, 2013, Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: implications for treatment cost-effectiveness. Hepatology, 57, 451–460. |
[12] | Broering R, Lu M, Schlaak JF, 2011, Role of Toll-like receptors in liver health and disease, Clin Sci (Lond), 121(10), 415-26. |
[13] | Wang Y, Li J, Wang X, Ye L, et al, 2014, Hepatitis C virus impairs TLR3 signaling and inhibits IFN-lambda 1 expression in human hepatoma cell line, Innate Immun, 20: 3-11. |
[14] | Firdaus R, Biswas A, Saha K, Mukherjee A, et al., 2014, Modulation of TLR 3, 7 and 8 Expressions in HCV Genotype 3 Infected Individuals: Potential Correlations of Pathogenesis and Spontaneous Clearance]. BioMed Research International, 2014, 1-7. |
[15] | Motavaf M, Noorbakhsh F, Alavian S, and Sharifi Z, 2014, Distinct Toll-like Receptor 3 and 7 Expression in Peripheral Blood Mononuclear Cells From Patients with Chronic Hepatitis C Infection, Hepat Mon, 14(4), e16421. |
[16] | Mohammed K I, Adel L, Ali-Eldin F, Eladawy S, 2013, Expression of Toll Like Receptors 3 & 7 in Peripheral Blood from Patients with Chronic Hepatitis C Virus Infection and Their Correlation with Interferon-α 1, The Egy J of Immunol, 20 (1), 13-22 . |
[17] | Dolganiuc. A, Garcia. C, Kodys. K, Szabo. G, 2006, Distinct toll-like receptor expression in monocytes and T cells in chronic HCV infection, World J Gastroenterol, 12(8), 1198-1204. |
[18] | Abdel-Raouf T. Ahmed A. Zaki W, 2014, Study of toll-like receptor 7 expression and interferon α in Egyptian patients with chronic hepatitis C Infectionand Hepatocellular Carcinoma Egy J of Medical Human Genetics, 15, 4, 2, 387-392. |
[19] | Domanski P., Colamonici O. R., 1996, The type-I interferon receptor. The long and short of it. Cytokine Growth Factor Rev. 7: 143–151. |
[20] | Lin H.H, Hsu C.S, Kao J.H, Chao Y.C, 2013, Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan Aliment Pharmacol The, 38: 415–423. |
[21] | Atencia R, Bustamante F J, Valdivieso A, Arrieta A et al, 2007, Differential expression of viral PAMP receptors mRNA in peripheral blood of patients with chronic hepatitis C infection. BMC Infectious Diseases, 7(9), 136-143. |
[22] | Puig M, Tosh K W, Schramm L M, Grajkowska L T, et al, 2012, TLR9 and TLR7 agonists mediate distinct type I IFN responses in humans and nonhuman primates in vitro and in vivo. J. Leuk. Biol. 91(1): 147-158. |
[23] | Umar M and Akhter T, 2016, New Direct Acting Antiviral Agents for the Treatment of Hepatitis C: 2016 and Beyond. Journal of the College of Physicians and Surgeons Pakistan, Vol. 26 (10): 843-850. |